eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Staphylococcus Aureus Infection

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Elizabeth P Baorto, MD, MPH, Director, Division of Pediatric Infectious Diseases, Atlantic Health System; David Baorto, MD, PhD, Medical Knowledge Engineer, Department of Medical Informatics, Columbia University Medical Center

Updated: Jan 23, 2009

Introduction

Background

Bacteria of the genus Staphylococcus are gram-positive cocci that are microscopically observed as individual organisms, in pairs, and in irregular, grapelike clusters. The term Staphylococcus is derived from the Greek term staphyle, meaning "a bunch of grapes." Staphylococci are nonmotile, non–spore-forming, and catalase-positive bacteria. The cell wall contains peptidoglycan and teichoic acid. The organisms are resistant to temperatures as high as 50°C, to high salt concentrations, and to drying. Colonies are usually large (6-8 mm in diameter), smooth, and translucent. The colonies of most strains are pigmented, ranging from cream-yellow to orange.

The ability to clot plasma continues to be the most widely used and generally accepted criterion for the identification of Staphylococcus aureus. One such factor, bound coagulase, also known as clumping factor, reacts with fibrinogen to cause organisms to aggregate. Another factor, extracellular staphylocoagulase, reacts with prothrombin to form staphylothrombin, which can convert fibrinogen to fibrin. Approximately 97% of human S aureus isolates possess both of these forms of coagulase.

S aureus is ubiquitous and may be a part of human flora found in the axillae, the inguinal and perineal areas, and the anterior nares. In 2001, von Eiff et al described 3 patterns of carriage: those who always carry a strain, those who carry the organism intermittently with changing strains, and a minority of people who never carry S aureus.¹ Persistent carriage is more common in children than in adults.

Wenzel and Perl (1995) found that, among healthy adults, carrier rates of 11-32% were detected in the general population, and a prevalence of 25% was detected in hospital personnel.² Using pulsed-field gel electrophoresis (PFGE) for molecular typing, von Eiff et al (2001) found that, in most patients with S aureus bacteremia, the isolate from the patient's blood is identical to that found in the anterior nares.¹ Curiously, community-associated methicillin-resistant S aureus (CA-MRSA) is rarely found in the anterior nares; rather, it colonizes the skin, particularly in the perineal area. It may also colonize the pharynx, gut, and vagina.

Pathophysiology

The organism may cause disease through tissue invasion and toxin production. The toxins liberated by the organism may have effects at sites distant from the focus of infection or colonization.

Tissue invasion

The postulated sequence of events that leads to infection is initiated with carriage of the organism. The organism is then disseminated via hand carriage to body sites where infection may occur (either through overt breaks in dermal surfaces, such as vascular catheterization or operative incisions, or through less evident breakdown in barrier function, such as eczema or shaving-associated microtrauma).

The hallmark of staphylococcal infection is the abscess, which consists of a fibrin wall surrounded by inflamed tissues enclosing a central core of pus containing organisms and leukocytes. From this focus of infection, the organisms may be disseminated hematogenously, even from the smallest abscess. The ability to elaborate proteolytic enzymes facilitates the process. This may result in pneumonia, bone and joint infection, and infection of the heart valves. In immunocompromised hosts (eg, patients with cancer who are neutropenic and have a central venous line), 20-30% develop serious complications or fatal sepsis following catheter-related S aureus bacteremia.

Persistent deep-seated infections have now been linked to small-colony variants of the organism. This population is more resistant to antibiotics and grows slowly. These organisms have been described in patients with cystic fibrosis and may contribute to the persistence of S aureus in these patients.

Toxin-mediated disease

The organism may also elaborate toxins that can cause specific diseases or syndromes. Enterotoxin-producing strains of S aureus cause one of the most common food-borne illnesses. The most common presentation is acute onset of vomiting and watery diarrhea 2-6 hours after ingestion. The symptoms are usually self-limited. The cause is the proliferation of toxin-producing organisms in uncooked or partially cooked food that an individual carrying the staphylococci has contaminated.

A rare but well-described disorder in neonates and young children is staphylococcal scalded skin syndrome (Ritter disease). The organism produces an exfoliative toxin produced by strains belonging to phage group II. Initial features include fever, erythema, and blisters, which eventually rupture and leave a red base. Gentle shearing forces on intact skin cause the upper epidermis to slip at a plane of cleavage in the skin, which is known as the Nikolsky sign. How the exfoliative toxins produce epidermal splitting has not been fully elucidated.

The most feared manifestation of S aureus toxin production is toxic shock syndrome (TSS). Although first described in children, it was most frequently associated with women using tampons during menstruation. Since the early 1990s, at least half of the cases have not been associated with menstruation. The syndrome is associated with strains that produce the exotoxin TSST-1, but strains that produce enterotoxins B and C may cause 50% of cases of nonmenstrual TSS. These toxins are superantigens, T-cell mitogens that bind directly to invariant regions of major histocompatibility complex class II molecules, causing an expansion of clonal T cells, followed by a massive release of cytokines. This cytokine release mediates the TSS; the resultant pathophysiology mimics that of endotoxic shock.

In a recent worldwide trend, the proportion of infections caused by CA-MRSA has increased. Initially noted in tertiary care centers, these infections are now increasingly common in the community. Resistance to methicillin confers resistance to all penicillinase-resistant penicillins and cephalosporins. This high level of resistance requires the mec gene that encodes penicillin-binding protein 2a. This protein has decreased binding affinity for most penicillins and cephalosporins. Methicillin resistance has a wide variety of phenotypic expression. Heterogeneous resistance, recognized in the first clinical isolates described, is the typical phenotype. In this case, all cells carry the genetic markers of resistance but only a small fraction of them express the phenotype. Less frequent is homogenous resistance, with a single population of cells that are inhibited only through high concentrations of antibiotics.

Methicillin-resistant S aureus (MRSA) was initially described in hospitalized populations. University affiliation and greater number of beds were institutional risk factors. In pediatric centers, number of beds, region, and metropolitan population correlated with increased risk. Since 1996, more patients with CA-MRSA have been described. The strains isolated from these patients are different from typical nosocomial organisms in their susceptibility patterns and in their PFGE characteristics. A clonal population, designated USA-300, has become the predominant circulating organism in most communities. Many of these strains produce the Panton-Valentine leukocidin, which is associated with a tendency to produce abscesses, invasiveness, thrombogenesis, and morbidity and mortality.

More recently, S aureus that is intermediately resistant to vancomycin has been reported in 2 hospitalized patients, which suggests that full resistance to vancomycin may eventually emerge.³ Although the possibility of interspecies transfer of vancomycin-resistance genes from vancomycin-resistant Enterococcus was originally considered as the cause of this phenomenon, none of the species isolated have carried vanA, vanB, vanC1, vanC2, or vanC3 genes. Of note, the clinical isolates with intermediate resistance to vancomycin were from patients who had undergone prolonged vancomycin therapy for MRSA. Morphologically, these isolates were found to have increased extracellular material associated with the cell wall that may have been selected for during a prolonged antibiotic course.

Frequency

United States

Numbers of both community-associated and hospital-acquired infections have increased in the past 20 years. From 1990-1992, data from the National Nosocomial Infections Surveillance System for the Centers for Disease Control and Prevention (CDC) revealed that S aureus was the most common cause of nosocomial pneumonia and operative wound infections and the second most common cause of nosocomial bloodstream infections.

Frequency of antibiotic resistance: In a disturbing trend, antibiotic resistance among these isolates has increased because of antibiotic pressure. Currently, less than 5% of clinical isolates remain sensitive to penicillin. Resistance to penicillin was reported as early as 1942 and is mediated by beta-lactamase, a serine protease that hydrolyzes the lactam ring. In the 1980s, MRSA emerged as a prominent hospital-based infection; consequently, the use of vancomycin increased. A CDC survey revealed that the proportion of methicillin-resistant isolates with sensitivity only to vancomycin increased from 22.8% in 1987 to 56.2% in 1997.⁴

Mortality/Morbidity

Morbidity and mortality from S aureus infection widely varies depending on the clinical entity. Although mortality is low in children with scalded skin syndrome, most fatalities are associated with delay in diagnosis.

Sex

The male-to-female ratio of skeletal infections is 2:1, mostly because boys are more likely to experience traumatic events.

Clinical

History

• Skin and soft tissue (impetigo): Typically, this starts as a small area of erythema that progresses into bullae (filled with cloudy fluid) that rupture and heal with the formation of a honey-colored crust. Although group A Streptococcus was once considered the primary agent, Staphylococcus aureus has become the major pathogen since the 1980s. S aureus exclusively causes bullous impetigo, which is observed less frequently in the United States. This form of disease seems to arise from healthy-appearing skin. The bullae rupture, leaving a denuded area with a varnish-like coating.
• Scalded skin syndrome (Ritter disease): An exfoliative toxin (see Toxin-mediated disease) causes this relatively rare syndrome, which takes the form of superficial fragile blisters that burst, leaving a tender base. The patient is often febrile and, occasionally, has mucopurulent eye discharge. This diagnosis should be made carefully, because scalded skin syndrome may be mistaken for erythema multiforme or toxic epidermal necrolysis, which can be treated with corticosteroids. Misdiagnosis delays treatment and allows exfoliation to progress, and corticosteroid therapy may potentiate bacterial superinfection. Although the mortality rate is low in children with this entity, most fatalities are associated with delay in diagnosis.
• Folliculitis, furuncle, and carbuncle: These are increasingly severe staphylococcal skin infections. Folliculitis is a tender pustule that involves the hair follicle. A furuncle involves both the skin and the subcutaneous tissues in areas with hair follicles, such as the neck, axillae, and buttocks. They are actually small abscesses characterized by exuding purulent material from a single opening. A carbuncle is an aggregate of connected furuncles and has several pustular openings. Skin infections may be self-limited, but they can also disseminate hematogenously and cause life-threatening septicemia.
• Bone infections (osteomyelitis)
• Children often present with sudden onset of fever and bony tenderness or a limp. The pain may be throbbing and severe; however, presentation in neonates can be subtle. Infants may appear well except for failure to move an extremity or pain on movement. Redness or swelling indicates that infection has spread into the subperiosteal space. Rupture of a focus of osteomyelitis into joint space can result in septic arthritis. This is often observed in neonates.
• Children with vertebral osteomyelitis present with back pain, and those younger than 3 years present with refusal to walk or with a limp. Occasionally, children with vertebral osteomyelitis present with incontinence. Children with discitis tend to present with less fever and often appear less ill than children with vertebral osteomyelitis.
• Septic arthritis: Typical findings include decreased range of motion, warmth, erythema, and tenderness of the joint with constitutional symptoms and fever. Infants (in whom the hip is the most commonly involved joint) are an exception, as these signs may be absent. The child typically lies with the involved joint abducted and externally rotated. Because pain fibers are located within the joint capsule, movements that compress the head of the femur into the acetabulum (eg, changing a diaper) cause pain. A portal of infection is almost never found, and the infection is nearly always unilateral. Patients with infection of the sacroiliac joint present with tenderness elicited during digital rectal examination and with pain during flexion, abduction, and external rotation of the hip.
• Endocarditis: The initial presentation of patients with S aureus endocarditis is fever and malaise. However, the disease has a more rapid onset than that caused by less virulent pathogens. Notably, on initial presentation, the usual physical stigmata are absent. Endocarditis may also involve healthy valves. For more detail, please see Endocarditis, Bacterial.
• Toxic shock syndrome (TSS)
• Staphylococcal TSS is a potentially life-threatening systemic bacterial intoxication. Case definition includes fever, diffuse macular erythema, and hypotension, with involvement of 3 or more of the following organ systems:
• GI - Emesis or diarrhea appears at the time of illness. Diarrhea is secretory and profuse, and is found in almost all patients with TSS but is uncommon in patients in septic shock.
• Muscular - Severe myalgia or elevated creatine kinase (CK) levels are observed. Myalgia may be one of the earliest manifestations of the disease.
• Renal - Elevation of BUN or creatinine levels or more than 5 WBCs per high-power field in the absence of a urinary tract infection is observed.
• Hepatic levels of bilirubin, serum glutamic-oxaloacetic transaminase (aspartate aminotransferase), and serum glutamic-pyruvic transaminase (alanine aminotransferase) are twice the upper limit of the reference range.
• Hematologic – The platelet count is less than 100,000/ μ L.
• Nervous system – Features include disorientation and alteration in consciousness with the absence of focal neurologic signs when fever and hypotension are absent.
• A probable case of TSS involves 5 of the above 6 findings.
• A confirmed case of TSS involves all 6 findings.
• The most striking aspect of the disease is the rapidity with which it can progress in a previously healthy individual of any age. This is especially true in postsurgical patients, particularly following nasal surgery, because this is an area commonly colonized with S aureus. Late-onset dermatologic findings include a red and pruritic maculopapular rash, desquamation of the fingers and toes, and telogen effluvium (see Toxic Shock Syndrome).
• Pneumonia: Cases of rapidly progressive and fatal staphylococcal pneumonia still occur, although they were much more common in the 1950s and early 1960s, when S aureus phage type 80/81 caused frequent disease in infants. Staphylococcal pneumonia most commonly occurs in infants, young children, and patients who are debilitated. This is a rapidly progressive disease. Patients with primary staphylococcal pneumonia present with a short prodrome of fever followed by rapid onset of respiratory distress, which may include tachypnea, retractions, and cyanosis. Patients may also have prominent GI tract symptoms. Staphylococcal pneumonia may also develop after influenza infection, which seems to occur preferentially among young adults (in whom mortality reaches 50%). Typically, the child seems to recover from a febrile illness only to once again develop an increasing fever and the symptoms mentioned above.
• Thrombophlebitis: Usually occurring in a hospitalized patient, thrombophlebitis is characterized by fever, pain, and, occasionally, erythema at the insertion site of an intravenous catheter. Occasionally, pus is expressed. Severe suppurative thrombophlebitis may occur in burn patients, with fewer than half of diagnoses made while the patients are alive.
• Deep tissue abscess and infection: Muscles (myositis and pyomyositis) and organs can become infected, including the parotid gland, eyes, liver, spleen, and kidneys. These infections typically cause fever with or without localizing pain.

Physical

• Skin and soft tissue (impetigo): The infection initially appears as a small area of erythema. Bullae (ie, blister-like lesions filled with cloudy fluid) appear as the disease progresses. As bullae heal, a honey-colored crust develops.
• Scalded skin syndrome (Ritter disease): Examination reveals superficial, fragile blisters that burst, leaving a tender base. Skin sloughs easily when touched, a condition termed the Nikolsky sign. Fever is often present, and mucopurulent eye discharge may be observed. As discussed above, the infection is often mistaken for erythema multiforme or toxic epidermal necrolysis. Misdiagnosis must be avoided.
• Folliculitis, furuncle, and carbuncle: Folliculitis is the appearance of a tender pustule involving a hair follicle. A furuncle is an apparent small abscess that exudes purulent material from a single opening. A carbuncle is an aggregate of furuncles with several openings.
• Bone infections (osteomyelitis): Fever, bony tenderness, or a limp indicate bone infections. Infants may appear well except for failure to move an extremity or pain on movement. Children with vertebral osteomyelitis present with back pain, and those younger than 3 years present with refusal to walk or with a limp. Occasionally, children with vertebral osteomyelitis have incontinence as a presenting symptom. Children with discitis tend to present with less fever and often appear less ill than children with vertebral osteomyelitis.
• Septic arthritis: Examination reveals warmth, erythema, and tenderness of the joint. Constitutional symptoms and fever are frequently observed. These findings may be absent in an infant. Children with infection of the sacroiliac joint present with tenderness elicited during digital rectal examination.
• Endocarditis: The clinical syndrome widely varies and may involve multiple organs. S aureus infection usually results in an acute course but may involve subacute disease. Most patients present with high fever. Chills and sweats and a new or worsened murmur may occur. Peripheral emboli such as Osler nodes, subungual hemorrhages, Janeway lesions, and Roth spots may be present. Other embolic phenomena may occur.
• TSS: TSS involves a fever of 38.9°C or higher. Hypotension occurs, either with blood pressure below the fifth percentile for age or with an orthostatic (lying to sitting) drop in diastolic blood pressure greater than or equal to 15 mm Hg. A diffuse, erythroderma-like rash is present. Conjunctival or vaginal hyperemia may be present. Patients may have altered sensorium, even when normotensive, or may be delirious, disoriented, or agitated without focal signs. Reddened lips and tongue may be observed. Later, on recovery, desquamation of hands and feet may occur; occasionally, alopecia occurs later.
• Pneumonia: Fever is present. Findings of respiratory distress include tachypnea, cyanosis, grunting, and retractions. Vomiting and abdominal distension occur. Clinical deterioration is rapid.
• Thrombophlebitis: Patients usually have a fever and, occasionally, have cutaneous involvement such as erythema, induration, or tenderness. Occasionally, pus is expressed at the insertion site of the catheter. The exit site often does not show signs of infection. Establishing infection of an intravascular device as the cause of fever in a hospitalized patient is a diagnosis of exclusion.
• Deep tissue abscess and infection: Localizing tenderness may be present, as may signs of inflammation.

Causes

• Skin and soft tissue (impetigo): Often occurring in young children, impetigo is spread within families and through close physical contact. Impetigo is more prevalent in warm, humid climates because of more opportunities for insect bites and cutaneous trauma. Impetigo may also be a complication of varicella. Diagnosis is usually made based on the characteristic appearance of the lesions. Bullous impetigo may also occur in endemic and epidemic patterns. Nursery outbreaks have been described, and some cases in infants have progressed to scalded skin syndrome or Ritter disease (described in History).
• Folliculitis, furuncle, and carbuncle: Recurrent staphylococcal skin infections develop in certain patients, such as those with impaired neutrophil function (eg, those with chronic granulomatous disease), patients with atopy and chronic eczema, and those with impaired circulation and diabetes mellitus. However, most patients with recurrent furunculosis are colonized with CA-MRSA but are otherwise healthy. Thus, an evaluation of the immune system in these individuals is seldom useful.
• Bone and joint infections (osteomyelitis): Osteomyelitis typically occurs in children prior to the age of epiphyseal closure. Osteomyelitis typically originates in the metaphysis of long bones in the region of most rapid growth. Osteomyelitis usually involves (in order of frequency) the lower end of the femur, the upper end of the tibia and humerus, and the radius. Most bone and joint infections result from hematogenous spread, but significant blunt trauma is a preceding event in approximately one third of cases. In addition, penetrating wounds, compound fractures, and orthopedic appliances may introduce microbial infection directly into bone. Notably, the male-to-female ratio of skeletal infections is 2:1, mostly because boys are more likely to experience traumatic events.
• Septic arthritis: Staphylococci are frequent etiologic agents of septic arthritis and, since the era of successful vaccination for Haemophilus influenzae, are now more predominant in younger age groups . Bacteria can enter the joint space through hematogenous spread, direct inoculation, or contiguous spread of infection. Because the synovial membrane has a high effective blood flow, a large number of bacteria may be delivered to the joint during a period of bacteremia. Inoculation can occur when a joint is punctured with a contaminated object, and many clinical studies reveal that the knee is more likely to be punctured. In the postantibiotic era, contiguous spread has been rare, with the exception of neonatal osteomyelitis.
• Endocarditis: Fortunately, S aureus endocarditis is rare in pediatric patients. It often involves adolescent intravenous drug users who do not have antecedent valvular disease. These patients usually present with right-sided disease with evidence of pulmonary disease, such as pulmonary abscesses or shifting infiltrates. In children with preexisting heart disease, endocarditis is often temporally related to cardiac surgery or catheterization. Children with prosthetic valves are particularly vulnerable because of the organism’s propensity to adhere to foreign materials. In addition, patients with indwelling vascular access devices are at risk, because infections from the skin can seed the catheter.
• TSS
  • Infection with toxin-producing S aureus in the absence of protective antibody is an antecedent. Younger patients may be at increased risk because they lack the protective antibodies to the enterotoxins and other exotoxins responsible for producing this clinical syndrome. However, other factors may be involved; Jacobsen et al (1989) demonstrated in a small study that not all patients without antibody develop true TSS when infected with a toxin-producing strain of the organism.⁵
  • Approximately 25% of all S aureus strains are toxigenic, and, at any time, roughly 4-10% of healthy individuals are colonized with these strains. In the 1980s, the disease was associated with the use of highly absorbent tampons in women during menstruation. Currently, many cases observed are nonmenstrual (eg, localized infections, surgery, infected varicella lesions, insect bites), and these now account for one third of all cases. These patients carry a higher mortality rate than those with menstrual TSS.
• Pneumonia: The primary form occurs without an extrapulmonary focus, presumably through direct inoculation to the lungs, and the secondary form results from hematogenous seeding of the lungs during endocarditis or bacteremia. Predisposing factors include infancy, chronic illness, and viral respiratory disease such as influenza. Patients with head injury and trauma who have nasopharyngeal carriage of S aureus are at increased risk of S aureus pneumonia.
• Thrombophlebitis: The causes are associated with infusion, including infected intravenous catheters and needles. The common point of entry for infection related to intravascular devices is the insertion site along the outside of the device.
• Deep tissue abscess and infection: These typically result from hematogenous seeding, although myositis or pyomyositis can result from contiguous spread of infection and endophthalmitis can follow trauma (injury or iatrogenic), for example.

The differential diagnoses of staphylococcal infections include the following:

• Impetigo - None
• Bullous impetigo
  • Pemphigus
  • Pemphigoid
  • Burn
  • Stevens-Johnson syndrome
  • Dermatitis herpetiformis
• Scalded skin syndrome (Ritter disease)
  • Nonaccidental injury
  • Scalding
  • Abrasion trauma
  • Sunburn
  • Erythema multiforme
  • Toxic epidermal necrolysis
• Bone and joint infections
  • Bone infarction (in patients with sickle cell disease)
  • Toxic synovitis
  • Leukemia
• Septic arthritis
  • Trauma
  • Deep cellulitis
  • Henoch-Schönlein purpura
  • Slipped capital femoral epiphysis
  • Legg-Calve-Perthes disease
  • Leukemia
  • Toxic synovitis
  • Metabolic diseases affecting joints (Ochronosis)
• Endocarditis - Bacteremia
• TSS
  • Staphylococcal scalded skin syndrome
  • Meningococcemia
  • Rubeola
  • Adenoviral infections
  • Dengue fever
  • Severe allergic drug reactions

Differential Diagnoses

Workup

Laboratory Studies

An erythromycin-induction test, or D-test, should always be performed with staphylococcal sensitivities to reveal inducible clindamycin resistance among community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

• Folliculitis, furuncle, and carbuncle: Make the diagnosis based on clinical appearance and, occasionally, on results of aspiration or incision and culture of purulent material from the lesion.
• Osteomyelitis: Blood culture results are positive in only 30-50% of pediatric patients. Therefore, cultures of bone aspirate are useful in obtaining the organism and planning for long-term therapy. In addition, C-reactive protein levels and erythrocyte sedimentation rate are generally elevated in acute disease.
• Septic arthritis: Examination of joint fluid, when obtained, is the primary means of diagnosis; the fluid should be sent to the laboratory for Gram stain and culture. In addition, the number and type of leukocytes should be determined. Median cell count in bacterial arthritis is 60.5 X 10⁹ cells with a neutrophil predominance of greater than 75%. Often, synovial fluid glucose levels are low. Yield of culture may be improved by directly inoculating synovial fluid into blood culture bottles.
• Endocarditis: The most important diagnostic procedure is the blood culture. Blood should be injected into hypertonic media if the patient has been exposed to antibiotics. Obtaining 3-5 sets of large-volume blood cultures within the first 24 hours is recommended.
• Pneumonia: Blood culture findings for S aureus are more likely to be positive in secondary disease than in primary disease (90% vs 20%). Because blood culture results are often negative, an adequate respiratory tract specimen should be obtained prior to initiating therapy; specimens may include endotracheal sampling, pleural fluid, or lung tap. Sputum is not considered adequate because the organism is frequently present in the upper respiratory secretions of healthy individuals.
• Thrombophlebitis: Although treatment is occasionally controversial, obtaining a blood culture through the intravenous line and a peripheral blood culture is usually recommended.

Imaging Studies

• Osteomyelitis: On plain film radiographs, destructive bone changes are usually observed 2 weeks after infection. This is because a 30-50% reduction in bone calcium content is required before an osteolytic lesion is visible. The clinical diagnosis of osteomyelitis is most often supported by findings on bone scan with technetium Tc99m–labeled diphosphonate. Increased tracer uptake reflects the inflammatory process in the bone lesion. However, this modality is not as useful in neonates or after trauma or surgery. MRI is the best imaging modality for defining purulent collections and for planning surgery.
• Septic arthritis: Plain radiographs show capsular swelling. They are most useful in revealing other causes of hip pain, such as Legg-Calve-Perthes disease. Radiographs should be obtained with the child in the frog leg position as well as with the legs extended and slightly internally rotated. Displacement of gluteal fat lines because of the swelling of the joint capsule is an early radiologic sign of septic arthritis. If a bone scan is performed, increased uptake on either side of the joint is visible. As pyogenic sacroiliitis is difficult to diagnose, the radiologic method of choice is MRI or CT scanning.
• Endocarditis: Echocardiography is a valuable adjunct. Two-dimensional echocardiography is more sensitive than the M-mode technique, and it has been used to reveal vegetations in patients with negative culture results. However, because of variable sensitivity, a negative finding does not exclude endocarditis. Transesophageal echocardiography is more sensitive than transthoracic echocardiography in the detection of intracardiac vegetations.
• Pneumonia: No radiologic features are highly specific, but the chest radiograph may provide information, especially in demonstrating its progression. Radiographs of patients with primary staphylococcal pneumonia may reveal unilateral consolidation, while patients with secondary staphylococcal pneumonia are more likely to demonstrate bilateral infiltrates on radiographs. Early in the disease course, the chest radiograph may reveal minimal infiltrates, but, within hours, they rapidly progress. Pleural effusion, pneumatoceles, and pneumothorax are also common.

Histologic Findings

• For scalded skin syndrome (Ritter disease), histologic examination of a skin biopsy specimen is the most helpful, because demonstration of midepidermal separation at the zona granulosa is diagnostic of this entity and excludes erythema multiforme in which dermoepidermal cleavage occurs.

Treatment

Medical Care

Because community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causes more than one half of all staphylococcal infections in most communities, empiric therapy with penicillins or cephalosporins is inadequate. Some experts recommend combination therapy with a penicillinase-resistant penicillin or cephalosporin (in case the organism is methicillin-sensitive S aureus [MSSA]) and clindamycin or a quinolone. Others suggest use of clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, or a quinolone. Finally, because of concerns about induction of resistance, some recommend using TMP-SMX and rifampin in combination, rather than singly.

• Impetigo, folliculitis, furuncle, carbuncle: Impetigo and other minor skin infections (ie, superficial or localized infections) may be treated with a topical agent such as mupirocin or retapamulin. However, most CA-MRSA strains are or readily become resistant to mupirocin. More extensive or serious skin disease and bullous impetigo are treated with oral antistaphylococcal agents, as noted above.
• Scalded skin syndrome (Ritter disease): As with any S aureus toxin–mediated disease, treatment should aim to eradicate the focus of infection and end toxin production. Administer large doses of intravenous antistaphylococcal agents, such as oxacillin (150 mg/kg/d), or a first-generation cephalosporin, such as cefazolin (100 mg/kg/d). In vitro, clindamycin has been shown to inhibit the synthesis of TSST-1 and is extremely effective in combination with one of the agents mentioned above. Children with denuded skin should be touched as little as possible. Topical antimicrobial agents have little use, because skin damage is self-limited once systemic antibiotics are administered.
• Osteomyelitis: Empirically, initiating a semisynthetic penicillin (eg, oxacillin [150 mg/kg/d]) and clindamycin (30-40 mg/kg/d) is a good choice for most cases of community-acquired osteomyelitis. In patients with allergy to penicillin, a first-generation cephalosporin and clindamycin (30-40 mg/kg/d) are an excellent alternative. Use vancomycin or linezolid when the other drugs mentioned are absolutely not tolerated or when resistance or the clinical course dictates. The duration of therapy is a controversial topic in the literature, but the consensus among multiple authors is that the minimum effective treatment time is 4-6 weeks. A switch to oral therapy is acceptable if the child is able to take oral antibiotics, is afebrile, and if he or she has demonstrated a good clinical response to parenteral antibiotics.
• Septic arthritis: As in osteomyelitis, initiate an appropriate antistaphylococcal drug (eg, oxacillin, which is penicillinase resistant; clindamycin; cefazolin) parenterally. These antibiotics readily reach joint fluid, and the concentration in the joint fluid is 30% of the serum value. Therapy usually continues for at least 4 weeks. Duration of parenteral therapy is often debated. Some authors have demonstrated efficacy with 1 week of parenteral therapy followed with 3 weeks of oral therapy. Consider a switch to oral therapy based on the considerations mentioned above. Joint fluid that reaccumulates should be removed, and a sample should be cultured to assess the efficacy of therapy and to make the patient more comfortable.
• Endocarditis
  • Duration of therapy for endocarditis, which is a life-threatening infection, is at least 4 weeks.
  • The combination of a beta-lactam and an aminoglycoside is advocated, because it increases bacterial killing in vitro and in animal models of endocarditis. In patients with MRSA, combinations of vancomycin with aminoglycosides should be used.
  • Rifampin, because of its lipid solubility, is another potent agent when used in combination with nafcillin and gentamicin or vancomycin and gentamicin, especially in patients with prosthetic valve endocarditis. Rifampin should never be used alone because resistance can develop.
  • The response to therapy is usually slow, and patients may continue to have bacteremia, fever, and leukocytosis for at least a week after therapy is initiated.
  • Some authors recommend obtaining blood cultures after the end of therapy.
  • Treatment with antibiotics is specific to the etiologic agent and its characteristics. For more information, see Endocarditis, Bacterial.

Surgical Care

• Osteomyelitis: Surgery is usually indicated to drain purulent material from the subperiosteal space or if infected foreign material is present.
• Septic arthritis: In an infant, septic arthritis of the hip and shoulder is a surgical emergency; these joints should be drained as soon as possible to prevent bony destruction. In addition, if a large amount of fibrin, tissue debris, or loculation is present, preventing adequate drainage with needle aspiration, the joint should be surgically drained.
• Endocarditis: If endocarditis occurs in the presence of an intracardiac foreign body, it may require removal.
• Toxic shock syndrome (TSS): All potential foci of infection should be explored and surgically drained.
• Thrombophlebitis: Remove the infected intravenous line in patients who are immunocompromised or severely ill or when infection is impossible to eradicate medically.

Medication

The major antibiotics active against the staphylococcal organism are presented here.

Antistaphylococcal antibiotics

Serious staphylococcal infections require treatment with parenteral penicillinase-resistant penicillin (eg, nafcillin, oxacillin) or first-generation or second-generation cephalosporins (eg, cephalexin, cefuroxime) plus clindamycin. Vancomycin is reserved for staphylococcal strains that are resistant to penicillinase-resistant penicillins (ie, MRSA) and clindamycin, or for when the patient has potentially life-threatening infection or intoxication. Mupirocin or retapamulin may be used for superficial localized infections (ie, impetigo).

Dicloxacillin

Binds to one or more penicillin-binding proteins, which, in turn, inhibits synthesis of bacterial cell walls. For treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when staphylococcal infection is suspected.

Dosing

Adult

125-500 mg PO q6h

Pediatric

<40 kilograms: 12.5-50 mg/kg/d PO divided q6h; doses up to 50-100 mg/kg/d have been used for PO therapy for osteomyelitis
>40 kilograms: Administer as in adults

Interactions

Decreases efficacy of PO contraceptives; may decrease effects of anticoagulants; probenecid and disulfiram may increase penicillin levels

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Prolonged elimination in neonates; toxicity may increase with renal dysfunction

Oxacillin

Bactericidal antibiotic that inhibits cell wall synthesis. Used in the treatment of infections caused by penicillinase-producing staphylococci.

Dosing

Adult

0.25-1 g IV q6h

Pediatric

150 mg/kg/d IV divided qid

Interactions

Oxacillin decreases effects of contraceptives and tetracycline; when administered concomitantly with disulfiram and probenecid, may increase oxacillin levels; increases anticoagulant effect with large IV doses

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Decreased elimination in neonates; can cause elevations in levels of transaminases with prolonged use

Nafcillin

Initial therapy for suspected penicillin G–resistant staphylococcal infections. Use parenteral therapy initially in severe infections. Change to PO therapy as condition warrants.

Dosing

Adult

0.5-1 g IV/IM q4-6h

Pediatric

Neonates:
<1200 grams or <7 days and 1200-2000 grams: 50 mg/kg/d IV divided q12h
<7 days and >2000 grams or >7 days and 1200-2000 grams: 75 mg/kg/d IV divided q8h
>7 days and >2000 grams: 100 mg/kg/d IV divided q6h
Children:
100-200 mg/kg/d IV divided qid; not to exceed 12 g/d
Reduce dose by 50% in renal or hepatic impairment

Interactions

CYP450 3A4 inducer; probenecid may decrease elimination of nafcillin; nafcillin may decrease half-life of warfarin and may decrease cyclosporine serum concentrations or interfere with the cyclosporine assay

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Elimination decreased in neonates; avoid during first 2 wk of life; monitor CBC count with prolonged use; may cause thrombophlebitis

Cephalexin (Keflex)

First-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora.

Dosing

Adult

250-500 mg PO q6h; not to exceed 4 g/d

Pediatric

25-100 mg/kg/d PO divided q6h; not to exceed 4 g/d

Interactions

Probenecid may increase and prolong cephalosporin plasma levels by competitively inhibiting renal tubular secretion; coadministration with aminoglycosides theoretically increases risk of nephrotoxicity

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Cefuroxime (Ceftin oral, Kefurox injection)

Broad-spectrum cephalosporin most closely resembling the second-generation cephalosporins. Cefuroxime is stable against beta-lactamase–producing organisms.

Dosing

Adult

250-500 mg PO bid; alternatively, 1 g IV q8h

Pediatric

Serious infections: 150 mg/kg/d IV divided q8h
Impetigo:
250-mg tab PO q12h
30 mg/kg/d PO susp divided bid; not to exceed 1 g/d

Interactions

Probenecid may increase and prolong cephalosporin plasma levels by competitively inhibiting renal tubular secretion; aminoglycosides may increase nephrotoxicity

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Periodically monitor renal function and CBC count; adjust dose or frequency with renal insufficiency (high doses may cause CNS toxicity); bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

Cefazolin

First-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin structure coverage.

Dosing

Adult

0.5-2 g IV q6-8h; not to exceed 12 g/d

Pediatric

50-100 mg/kg/d IV divided q8h; not to exceed 6 g/d

Interactions

Probenecid prolongs effect of cefazolin; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine-dip test results for glucose

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Monitor renal function parameters when used with other nephrotoxic drugs; monitor CBC count with prolonged use; dosing in renal impairment: administer q24h if CrCl <10 mL/min, administer q12h if CrCl 10-30 mL/min

Amoxicillin and clavulanate (Augmentin)

Drug combination treats bacteria resistant to beta-lactam antibiotics. For children >3 mo, base dosage regimen on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (ie, 250/125) versus 250-mg chewable tab (ie, 250/62.5), do not use 250-mg tab until child is >40 kg.

Dosing

Adult

250-500 mg PO q8h; not to exceed 2 g/d

Pediatric

<3 months: 30 mg (based on amoxicillin component) per kg/d PO divided q12h
Use 125 mg/5 mL PO susp
>3 months and <40 kilograms: 45 mg (based on amoxicillin component) per kg/d PO divided bid/tid
>40 kilograms: Administer as in adults

Interactions

Increased risk of amoxicillin rash with concurrent allopurinol; probenecid and disulfiram may increase penicillin levels

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Increased risk of maculopapular rash with concurrent EBV infection, CMV infection, or acute lymphocytic leukemia

Vancomycin (Lyphocin, Vancocin, Vancoled)

Potent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated in patients who are unable to receive or who have not responded to penicillins and cephalosporins or for infections with resistant staphylococci. Use CrCl to adjust dose in patients diagnosed with renal impairment.

Dosing

Adult

0.5 g IV q6h or 1 g IV q24h

Pediatric

Neonates:
<7 days and >2000 grams: 30 mg/kg/d IV divided q12h
>7 days and >2000 grams: 45 mg/kg/d IV divided q8h
<1 month and <1200 grams: 15 mg/kg/d IV q24h
<1 month and 1200-2000 grams: 20-30 mg/kg/d IV divided q12-18h
Infants >1 month and children: 40 mg/kg/d IV divided q8h
Seriously ill cancer patients and patients with suspected CNS infection: 60 mg/kg/d IV divided q6h
The necessity of monitoring drug levels is debated; to achieve an adequate therapeutic level in severe infections, the upper range of the peak (40 mcg/mL) should be reached

Interactions

Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants

Contraindications

Documented hypersensitivity; avoid using with prior hearing loss

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Use with caution in patients with renal impairment or on other nephrotoxic or ototoxic drugs; may cause facial flushing due to histamine release (ie, red man syndrome); flushing usually resolves by slowing IV infusion to administration over 2 h and by administering antihistamines; adjust daily dosing frequency in renal impairment (ie, monitor serum levels and CrCl)

Clindamycin (Cleocin)

Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, arresting RNA-dependent protein synthesis.

Dosing

Adult

150-450 mg PO q6h
1.2-1.8 g/d IV divided bid/qid; may increase dose, not to exceed 4.8 g/d

Pediatric

10-30 mg/kg/d PO divided q6-8h
25-40 mg/kg/d IV divided q6-8h; not to exceed 4.8 g/d

Interactions

Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis through allowing overgrowth of Clostridium difficile (inform patient to report severe diarrhea immediately)

Daptomycin (Cubicin)

First of new antibiotic class termed cyclic lipopeptides. Binds to bacterial membranes and causes rapid membrane potential depolarization, thereby inhibiting protein, DNA, and RNA synthesis, and, ultimately, causing cell death. Indicated to treat complicated skin and skin structure infections caused by S aureus (including methicillin-resistant strains), S pyogenes, S agalactiae, S dysgalactiae, and E faecalis (vancomycin-susceptible strains only). Indicated for skin and skin structure infections.

Dosing

Adult

CrCl >30 mL/min: 4 mg/kg IV q24h infused over 30 min
CrCl <30 mL/min: 4 mg/kg IV q48h (including hemodialysis or CAPD)

Pediatric

<18 years: Not established
>18 years: Administer as in adults

Interactions

Coadministration with tobramycin slightly increase daptomycin Cmax and AUC and decreases tobramycin Cmax and AUC; may experience additive effects with other drugs causing myopathy (eg, HMG CoA reductase inhibitors)

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Decrease dose with renal function <30 mL/min; pseudomembranous colitis may occur; may cause muscle pain or weakness; monitor CPK levels and discontinue daptomycin upon elevated CPK and unexplained myopathy or marked CPK elevation (10X upper limit of reference range); not indicated for pneumonia (higher death rate in daptomycin-treated patients during phase III trials); not compatible with dextrose-containing solutions

Linezolid (Zyvox)

Prevents formation of functional 70S initiation complex, which is essential for bacterial translation process. Bacteriostatic against staphylococci.

Dosing

Adult

400-600 mg PO/IV q12h

Pediatric

Preterm neonate <7 days: 10 mg/kg PO/IV q12h
Term neonates-12 years: 10 mg/kg PO/IV q8h
>12 years: Administer as in adults

Interactions

May cause hypertension when used concomitantly with adrenergic agents including pseudoephedrine, sympathomimetic agents, vasopressor or dopaminergic agents (reduce dose of dopamine or epinephrine if concurrent use required); serotonin syndrome may occur if used concomitantly with serotonergic agents including tricyclic antidepressants, meperidine, dextromethorphan, trazodone, venlafaxine, and SSRIs; may cause myelosuppression or pseudomembranous colitis inhibitors

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Has mild MAOI properties and may have the same interactions as other MAOIs; caution in uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism; caution in patients who are at increased risk of bleeding, have preexisting thrombocytopenia, receive concomitant medications that may decrease platelet count or function, or who may require >2 wk of therapy (monitor platelet counts); unnecessary use may lead to development of drug resistance; may cause peripheral or optic neuropathy

Rifampin (Rifadin injection/oral, Rimactane oral)

Inhibits RNA synthesis in bacteria by binding to beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription.

Dosing

Adult

S aureus: 600 mg/d PO/IV with other antibiotics

Pediatric

S aureus: 15 mg/kg/d PO/IV divided q12h with other antibiotics

Interactions

Induces microsomal enzymes, which may decrease effects of acetaminophen, PO anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, PO contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, digoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, or tocainide; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid or pyrazinamide may result in higher rate of hepatotoxicity than with either agent alone (discontinue one or both agents if alterations in LFT results occur); additive hepatotoxic effect with halothane

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor liver function periodically; stains body fluids orange; soft contact lenses may be permanently stained; obtain CBC counts and baseline clinical chemistries prior to and throughout therapy; in liver disease, weigh benefits against risk of further liver damage; interruption of therapy and high-dose intermittent therapy are associated with thrombocytopenia that is reversible if therapy is discontinued as soon as purpura occurs; if treatment is continued or resumed after appearance of purpura, cerebral hemorrhage or death may occur

Sulfamethoxazole and trimethoprim (Bactrim, Septra)

Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

Dosing

Adult

160/800 mg PO q12h

Pediatric

<2 years: Do not administer
>2 years: 6-12 mg of trimethoprim/kg/d in 2 doses

Interactions

May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine

Contraindications

Documented hypersensitivity; megaloblastic anemia due to folate deficiency; age <2 mo

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not use during last trimester of pregnancy because of potential toxicity to newborn (eg, jaundice, hemolytic anemia, kernicterus)
Dosage adjustments (adult adjustments)
CrCl (mL/min) 80-50: Recommended IV dose q18h
CrCl 50-10: Recommended IV dose q24h
CrCl <10: Not recommended
HD: 4-5 mg/kg after HD
During peritoneal dialysis: 0.16-0.8 g q48h
Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBC count frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, those who have chronic alcoholism, who are elderly, who are receiving anticonvulsant therapy, or who have malabsorption syndrome); hemolysis may occur in individuals deficient in G-6-PD; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation

Mupirocin (Bactroban)

For elimination of S aureus. Inhibits bacterial growth by inhibiting RNA and protein synthesis.

Dosing

Adult

Apply small amount topically to affected area 2-5 times per d for 5-14 d
Apply intranasal ointment 2-4 times per d and topical cream or ointment 3-5 times per d

Pediatric

Apply as in adults

Interactions

Concurrent intranasal administration of other medication not studied

Contraindications

Documented hypersensitivity; hypersensitivity to polyethylene glycol

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

For topical use only; avoid contact with eyes; patients with burns or open wounds can absorb toxic levels of polyethylene glycol; may irritate mucous membranes; overgrowth of nonsusceptible organisms can result with prolonged use

Retapamulin (Altabax)

Topical antibiotic available as a 1% ointment. First of new antibiotic class called pleuromutilins. Inhibits protein synthesis by binding to 50S subunit on ribosome. Indicated for impetigo caused by Staphylococcus aureus or Streptococcus pyogenes.

Dosing

Adult

Apply topically to affected site bid for 5 d

Pediatric

<9 months: Not established
>9 months: Apply as in adults

Interactions

None known

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May cause irritation at application site (1.4%); avoid application to eye area; keep out of reach of children

Blood products

These agents stimulate an immune response and offer transient protection while the host immune system develops antibodies.

Immune globulin, intravenous (Carimune, Gamunex, Polygam S/D)

Actions include neutralizing circulating myelin antibodies through anti-idiotypic antibodies, down-regulating proinflammatory cytokines (including interferon gamma), blocking Fc receptors on macrophages, suppressing inducer T and B cells, and augmenting suppressor T cells. Also blocks the complement cascade and promotes remyelination. May increase CSF IgG (10%).
IVIG has been shown to have high concentration of TSST-1 and the staphylococcal enterotoxins implicated in the pathogenesis of TSS. These antibodies may interfere with the binding of toxins that cause TSS.

Dosing

Adult

400 mg/kg IV as single dose infused over several hours

Pediatric

Administer as in adults

Interactions

Globulin preparation may interfere with immune response to live virus vaccine (MMR) and reduce efficacy (do not administer within 3 months of vaccine)

Contraindications

Documented hypersensitivity; IgA deficiency

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Check serum IgA before IVIG (use an IgA-depleted product if deficient, eg, Gammagard S/D); infusions may increase serum viscosity and thromboembolic events; infusions may increase risk of migraine attacks, aseptic meningitis (10%), urticaria, pruritus, or petechiae (2-30 d postinfusion)
Increases risk of renal tubular necrosis in elderly patients and in patients with diabetes, volume depletion, and preexisting kidney disease; lab result changes associated with infusions include elevated antiviral or antibacterial antibody titers for 1 mo, 6-fold increase in ESR for 2-3 wk, and apparent hyponatremia

Follow-up

Further Outpatient Care

• Appropriately monitor renal function, CBC count, and serum hepatic transaminase levels while patients with Staphylococcus aureus infection are undergoing therapy.

Complications

• S aureus infection may result in pneumonia, bone and joint infection, and infection of the heart valves.  
• In immunocompromised hosts (eg, patients with cancer who are neutropenic and have a central venous line), 20-30% develop serious complications or fatal sepsis following catheter-related S aureus bacteremia.
• Community-associated methicillin-resistant S aureus (CA-MRSA) infection is more serious and is associated with thrombogenesis.

Patient Education

• For excellent patient education resources, visit eMedicine's Women's Health Center and Skin, Hair, and Nails Center. Also, see eMedicine's patient education articles Toxic Shock Syndrome and Boils.

Miscellaneous

Medicolegal Pitfalls

• Scalded skin syndrome (Ritter disease) is often mistaken for erythema multiforme or toxic epidermal necrolysis, which may be treated with steroids. Misdiagnosis delays treatment and allows exfoliation to progress, and steroid therapy may potentiate bacterial superinfection. Most fatalities are associated with delay in diagnosis.
• Another potential medical pitfall is failure to realize that, in an infant, septic arthritis of the hip and shoulder is a surgical emergency. These joints should be drained as soon as possible to prevent bony destruction. In addition, if a large amount of fibrin, tissue debris, or loculation is present, which prevents adequate drainage with needle aspiration, the joint should be surgically drained.

References

1. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. Jan 4 2001;344(1):11-6. [Medline].

2. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. Sep 1995;31(1):13-24. [Medline].

3. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. Feb 18 1999;340(7):493-501. [Medline].

4. CDC. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. Jul 11 1997;46(27):626-8, 635. [Medline].

5. Jacobson JA, Kasworm E, Daly JA. Risk of developing toxic shock syndrome associated with toxic shock syndrome toxin 1 following nongenital staphylococcal infection. Rev Infect Dis. Jan-Feb 1989;11 Suppl 1:S8-13. [Medline].

6. Abrahamian FM, Moran GJ. Methicillin-resistant Staphylococcus aureus infections. N Engl J Med. Nov 15 2007;357(20):2090; author reply 2090. [Medline].

7. Aldin AS, Kinzl L, Eisele R. [Severe complications of Staphylococcus aureus infection in the child]. Unfallchirurg. Jan 2001;104(1):85-90. [Medline].

8. American Academy of Pediatrics. Toxic shock syndrome. In: Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2006:660-5.

9. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. Sep 2007;28(9):1047-53. [Medline].

10. Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. Nov 2007;194(5):606-10. [Medline].

11. Baartmans MG, Maas MH, Dokter J. Neonate with staphylococcal scalded skin syndrome. Arch Dis Child Fetal Neonatal Ed. Jan 2006;91(1):F25. [Medline].

12. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. Jun 24 1992;267(24):3315-6. [Medline].

13. Bhalla A, Aron DC, Donskey CJ. Staphylococcus aureus intestinal colonization is associated with increased frequency of S. aureus on skin of hospitalized patients. BMC Infect Dis. 2007;7:105. [Medline].

14. Brinsley-Rainisch KJ, Cochran RL, Pearson ML. Dermatologists' perceptions and practices related to community-associated methicillin-resistant Staphylococcus aureus infections. Am J Infect Control. Nov 2008;36(9):668-71. [Medline].

15. Browne LP, Mason EO, Kaplan SL, Cassady CI, Krishnamurthy R, Guillerman RP. Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol. Aug 2008;38(8):841-7. [Medline].

16. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med. Apr 1999;27(4):798-801. [Medline].

17. Casas I, Sopena N, Esteve M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus carriage at hospital admission. Infect Control Hosp Epidemiol. Nov 2007;28(11):1314-7. [Medline].

18. CDC. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns--Chicago and Los Angeles County, 2004. MMWR Morb Mortal Wkly Rep. Mar 31 2006;55(12):329-32. [Medline].

19. CDC. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999. JAMA. Sep 22-29 1999;282(12):1123-5. [Medline].

20. CDC. Outbreak of staphylococcal food poisoning associated with precooked ham--Florida, 1997. MMWR Morb Mortal Wkly Rep. Dec 19 1997;46(50):1189-91. [Medline].

21. Dancer SJ. Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet Infect Dis. Feb 2008;8(2):101-13. [Medline].

22. Datta F, Erb T, Heininger U, et al. A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with Staphylococcus aureus in patients admitted to children's hospitals in Switzerland. Clin Infect Dis. Oct 1 2008;47(7):923-6. [Medline].

23. Daum RS. Removing the golden coat of Staphylococcus aureus. N Engl J Med. Jul 3 2008;359(1):85-7. [Medline].

24. David MD, Kearns AM, Gossain S, Ganner M, Holmes A. Community-associated meticillin-resistant Staphylococcus aureus: nosocomial transmission in a neonatal unit. J Hosp Infect. Nov 2006;64(3):244-50. [Medline].

25. Dohin B, Gillet Y, Kohler R, et al. Pediatric Bone and Joint Infections Caused by Panton-Valentine Leukocidin-Positive Staphylococcus aureus. Pediatr Infect Dis J. Nov 2007;26(11):1042-1048. [Medline].

26. Faden H. Mastitis in children from birth to 17 years. Pediatr Infect Dis J. Dec 2005;24(12):1113. [Medline].

27. Faden H, Rose R, Lesse A, Hollands C, Dryja D, Glick PL. Clinical and molecular characteristics of staphylococcal skin abscesses in children. J Pediatr. Dec 2007;151(6):700-3. [Medline].

28. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. Jan 2008;8(1):53-66. [Medline].

29. Farrell AM. Staphylococcal scalded-skin syndrome. Lancet. Sep 11 1999;354(9182):880-1. [Medline].

30. Feigen RD, Cherry JD. Coagulase positive staphylococcal infections. In: Feigen RD, Cherry JD, eds. Textbook of Pediatric Infectious Disease. Philadelphia, Pa: WB Saunders Co; 1998:Chapters 32,64,85.

31. Fergie J, Purcell K. The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections. Pediatr Infect Dis J. Jan 2008;27(1):67-68. [Medline].

32. Fernandez M, Carrol CL, Baker CJ. Discitis and vertebral osteomyelitis in children: an 18-year review. Pediatrics. Jun 2000;105(6):1299-304. [Medline].

33. Fortunov RM, Hulten KG, Hammerman WA, Mason EO Jr, Kaplan SL. Evaluation and Treatment of Community-Acquired Staphylococcus aureus Infections in Term and Late-Preterm Previously Healthy Neonates. Pediatrics. Nov 2007;120(5):937-945. [Medline].

34. Frank AL. Staphylococcus aureus: a moving target. J Pediatr. Dec 2007;151(6):561-3. [Medline].

35. Fritz SA, Garbutt J, Elward A, Shannon W, Storch GA. Prevalence of and risk factors for community-acquired methicillin-resistant and methicillin-sensitive staphylococcus aureus colonization in children seen in a practice-based research network. Pediatrics. Jun 2008;121(6):1090-8. [Medline].

36. Gafur OA, Copley LA, Hollmig ST, Browne RH, Thornton LA, Crawford SE. The impact of the current epidemiology of pediatric musculoskeletal infection on evaluation and treatment guidelines. J Pediatr Orthop. Oct-Nov 2008;28(7):777-85. [Medline].

37. Gonzalez BE, Kaplan SL. Severe staphylococcal infections in children. Pediatr Ann. Oct 2008;37(10):686-93. [Medline].

38. Gonzalez BE, Teruya J, Mahoney DH Jr, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. May 2006;117(5):1673-9. [Medline].

39. Gorwitz RJ. A Review of Community-Associated Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections. Pediatr Infect Dis J. Jan 2008;27(1):1-7. [Medline].

40. Gorwitz RJ. Understanding the Success of Methicillin-Resistant Staphylococcus aureus Strains Causing Epidemic Disease in the Community. J Infect Dis. Jan 15 2008;197(2):179-82. [Medline].

41. Greene JN. Infections Related to Vascular Access Devices. Cancer Control. Oct 1996;3(5):456-464. [Medline].

42. Hamilton SM, Bryant AE, Carroll KC, et al. In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis. Dec 15 2007;45(12):1550-8. [Medline].

43. Heininger U, Datta F, Gervaix A, et al. Prevalence of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in children a multicenter cross-sectional study. Pediatr Infect Dis J. Jun 2007;26(6):544-6. [Medline].

44. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. Apr 2006;144(1):41-7. [Medline].

45. Huang YC, Ho CF, Chen CJ, Su LH, Lin TY. Nasal Carriage of Methicillin-Resistant Staphylococcus aureus in Household Contacts of Children With Community-Acquired Diseases in Taiwan. Pediatr Infect Dis J. Nov 2007;26(11):1066-1068. [Medline].

46. Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J. Apr 2006;25(4):349-53. [Medline].

47. Hussain A, Robinson G, Malkin J, Duthie M, Kearns A, Perera N. Purpura fulminans in a child secondary to Panton-Valentine leukocidin-producing Staphylococcus aureus. J Med Microbiol. Oct 2007;56(Pt 10):1407-9. [Medline].

48. Jaggi P, Paule SM, Peterson LR, Tan TQ. Characteristics of Staphylococcus aureus infections, Chicago Pediatric Hospital. Emerg Infect Dis. Feb 2007;13(2):311-4. [Medline].

49. Jensen JU, Jensen ET, Larsen AR, et al. Control of a methicillin-resistant Staphylococcus aureus (MRSA) outbreak in a day-care institution. J Hosp Infect. May 2006;63(1):84-92. [Medline].

50. Jeyaratnam D, Reid C, Kearns A, Klein J. Community associated MRSA: an alert to paediatricians. Arch Dis Child. Jun 2006;91(6):511-2. [Medline].

51. John Jr JF, Lindsay JA. Clones and Drones: Do Variants of Panton-Valentine Leukocidin Extend the Reach of Community-Associated Methicillin-Resistant Staphylococcus aureus?. J Infect Dis. Jan 4 2008;[Medline].

52. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect. Mar 2008;14 Suppl 2:3-9. [Medline].

53. Kahl B, Herrmann M, Everding AS, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. Apr 1998;177(4):1023-9. [Medline].

54. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis. Jul 2006;17(3):113-9. [Medline].

55. Kapoor V, Travadi J, Braye S. Staphylococcal scalded skin syndrome in an extremely premature neonate: a case report with a brief review of literature. J Paediatr Child Health. Jun 2008;44(6):374-6. [Medline].

56. Khangura S, Wallace J, Kissoon N, Kodeeswaran T. Management of cellulitis in a pediatric emergency department. Pediatr Emerg Care. Nov 2007;23(11):805-11. [Medline].

57. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. Dec 2007;13(12):1840-6. [Medline].

58. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. Oct 17 2007;298(15):1763-71. [Medline].

59. Krugman. Staphylococcus Aureus. In: Katz SL, Gershon AA, Hotez PJ, eds. Krugman's Infectious Diseases of Children. 10th. St. Louis, Mo: CV Mosby; 1998:Chapter 19.

60. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. Jan 15 2006;193(2):172-9. [Medline].

61. Ladhani S, Joannou CL. Difficulties in diagnosis and management of the staphylococcal scalded skin syndrome. Pediatr Infect Dis J. Sep 2000;19(9):819-21. [Medline].

62. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. Oct 2007;120(10 Suppl 1):S13-20. [Medline].

63. Lee TC, Carrick MM, Scott BG, Hodges JC, Pham HQ. Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital. Am J Surg. Dec 2007;194(6):809-12; discussion 812-3. [Medline].

64. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med. Oct 2007;120(10 Suppl 1):S28-33. [Medline].

65. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. Nov 2007;28(11):1290-8. [Medline].

66. Lowy FD. Staphylococcus aureus infections. N Engl J Med. Aug 20 1998;339(8):520-32. [Medline].

67. Mangini E, Segal-Maurer S, Burns J, et al. Impact of contact and droplet precautions on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus infection. Infect Control Hosp Epidemiol. Nov 2007;28(11):1261-6. [Medline].

68. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am. Dec 1997;11(4):813-49. [Medline].

69. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. Feb 2007;13(2):236-42. [Medline].

70. McCaskill ML, Mason EO Jr, Kaplan SL, Hammerman W, Lamberth LB, Hulten KG. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J. Dec 2007;26(12):1122-7. [Medline].

71. Mertz PM, Cardenas TC, Snyder RV, Kinney MA, Davis SC, Plano LR. Staphylococcus aureus virulence factors associated with infected skin lesions: influence on the local immune response. Arch Dermatol. Oct 2007;143(10):1259-63. [Medline].

72. Moumile K, Cadilhac C, Lina G. Severe osteoarticular infection associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Diagn Microbiol Infect Dis. Sep 2006;56(1):95-7. [Medline].

73. Murray PR, Baron EJ, Pfaller FC. Micrococci and Staphylococci. In: Murray PR, Baron EJ, Pfaller MA, Tenover TC, Yolken RH, eds. Manual of Clinical Microbiology. 7^th ed. ASM Press:264-272.

74. Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis. Nov 1 2007;45(9):1132-40. [Medline].

75. O'Hara FP, Guex N, Word JM, Miller LA, Becker JA, Walsh SL. A Geographic Variant of the Staphylococcus aureus Panton-Valentine Leukocidin Toxin and the Origin of Community-Associated Methicillin-Resistant S. aureus USA300. J Infect Dis. Jan 15 2008;197(2):187-194. [Medline].

76. Park JY, Jin JS, Kang HY, et al. A comparison of adult and pediatric methicillin-resistant Staphylococcus aureus isolates collected from patients at a university hospital in Korea. J Microbiol. Oct 2007;45(5):447-52. [Medline].

77. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. Feb 15 2008;46(4):584-93. [Medline].

78. Rim JY, Bacon AE 3rd. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus colonization in a random sample of healthy individuals. Infect Control Hosp Epidemiol. Sep 2007;28(9):1044-6. [Medline].

79. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of beta- lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. Nov 2000;44(11):3055-60. [Medline]. [Full Text].

80. Ruebner R, Keren R, Coffin S, Chu J, Horn D, Zaoutis TE. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics. Apr 2006;117(4):1210-5. [Medline].

81. Saavedra-Lozano J, Mejias A, Ahmad N, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. Jul-Aug 2008;28(5):569-75. [Medline].

82. Sahu DN, Thomson S, Salam A, Morton G, Hodgkins P. Neonatal methicillin resistant Staphylococcus aureus conjunctivitis. Br J Ophthalmol. Jun 2006;90(6):794-5. [Medline].

83. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R. Daptomycin in the treatment of bacteremia. Am J Med. Oct 2007;120(10 Suppl 1):S21-7. [Medline].

84. Seybold U, Halvosa JS, White N, Voris V, Ray SM, Blumberg HM. Emergence of and risk factors for methicillin-resistant Staphylococcus aureus of community origin in intensive care nurseries. Pediatrics. Nov 2008;122(5):1039-46. [Medline].

85. Stacey DH, Fox BC, Poore SO, Bentz ML, Gutowski KA. Community-acquired methicillin-resistant staphylococcus aureus: diagnosis and treatment update for plastic surgeons. Plast Reconstr Surg. Oct 2008;122(4):120e-7e. [Medline].

86. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. Jan 15 2007;195(2):202-11. [Medline].

87. Tacconelli E, Cataldo MA. Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opin Pharmacother. Oct 2007;8(15):2505-18. [Medline].

88. Tolan RW Jr. Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis. Jul 1993;17(1):43-5. [Medline].

89. Tolan RW Jr. Community-associated methicillin-resistant Staphylococcus aureus: overview of our current understanding. US Infectious Disease 2007 [serial online]. November 2007;II:52-4. Available from: Touch Briefings, PLC. Accessed March 26, 2008. Available at http://www.touchbriefings.com/cdps/cditem.cfm?nid=2930&cid=5.

90. Velissariou IM. Linezolid in children: recent patents and advances. Recent Patents Anti-Infect Drug Disc. Jan 2007;2(1):73-7. [Medline].

91. Viallon A, Marjollet O, Berthelot P, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED. Am J Emerg Med. Oct 2007;25(8):880-6. [Medline].

92. Wendt C, Schinke S, Wurttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol. Sep 2007;28(9):1036-43. [Medline].

93. West SK, Plantenga MS, Strausbaugh LJ,. Use of decolonization to prevent staphylococcal infections in various healthcare settings: results of an Emerging Infections Network survey. Infect Control Hosp Epidemiol. Sep 2007;28(9):1111-3. [Medline].

94. Wilson AP, Hayman S, Whitehouse T, et al. Importance of the environment for patient acquisition of methicillin-resistant Staphylococcus aureus in the intensive care unit: a baseline study. Crit Care Med. Oct 2007;35(10):2275-9. [Medline].

95. Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J. Apr 2006;25(4):343-8. [Medline].

96. Zhang K, McClure JA, Elsayed S, Tan J, Conly JM. Coexistence of Panton-Valentine Leukocidin-Positive and -Negative Community-Associated Methicillin-Resistant Staphylococcus aureus USA400 Sibling Strains in a Large Canadian Health-Care Region. J Infect Dis. Jan 15 2008;197(2):195-204. [Medline].

97. Zingg W, Posfay-Barbe KM, Pittet D. Healthcare-associated infections in neonates. Curr Opin Infect Dis. Jun 2008;21(3):228-34. [Medline].

Keywords

Staphylococcus aureus, abscess, bacteremia, carbuncle, cellulitis, community-acquired methicillin-resistant S aureus, community-associated methicillin-resistant S aureus, CA-MRSA, conjunctivitis, empyema, endocarditis, folliculitis, furuncle, impetigo, methicillin-resistant S aureus, MRSA, methicillin-sensitive S aureus, MSSA, osteomyelitis, pneumonia, Ritter disease, scalded skin syndrome, septic arthritis, S aureus, Staphylococcus aureus infection, thrombophlebitis, toxic shock syndrome, TSS, staphylococcal toxic shock syndrome, wound infection

Contributor Information and Disclosures

Author

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching

Coauthor(s)

Elizabeth P Baorto, MD, MPH, Director, Division of Pediatric Infectious Diseases, Atlantic Health System
Disclosure: Nothing to disclose.

David Baorto, MD, PhD, Medical Knowledge Engineer, Department of Medical Informatics, Columbia University Medical Center
Disclosure: Nothing to disclose.

Medical Editor

José Rafael Romero, MD, Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center
José Rafael Romero, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, New York Academy of Sciences, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus
Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting; Pfizer Honoraria Consulting

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)